Evaluation of innate lymphoid cells and their subsets in atopic dermatitis patients with and without dupilumab therapy

Click to increase image sizeClick to decrease image size

Author Contribution

Assoc. Prof. Jarmila Čelakovská, M.D., Ph.D – the main investigator

Department of Dermatology and Venereology Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, Czech Republic

• selection of the patients, dermatological examination and recommendations for the laboratory examination

• processing of all results

• writing of the manuscript

RNDr. Eva Čermáková

Department of Medical Biophysics, Medical Faculty of Charles University, Hradec Králové, Czech Republic

• statistical analysis

Petra Boudková, MSc. Eng.

Department of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic

• laboratory examination, flow cytometry

Prof. RNDr. Ctirad Andrýs, CSc

Department of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic

• control of laboratory examination

Prof. RNDr. Jan Krejsek CSc

Department of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic

professional cooperation, supervision

This study is approved by Ethics committee

This study was approved by Ethics committee of the Faculty Hospital Hradec Králové, Charles University of Prague, Czech Republic. Reference number is: 2021 10 P 03. The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board - Ethics committee of the Faculty Hospital Hradec Králové, Charles University of Prague, Czech Republic. Data of Approval 4 September, 2021.

Informed consent was obtained from all subjects involved in the study.

Disclosure statement

Jarmila Čelakovská, Eva Čermákova, Petra Boudková, Ctirad Andrýs, Jan Krejsek have nothing to disclose.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Medical writing/Editorial assistance

The article was written by the main author, no other services and Editorial assistence were needed.

Prior publication

This manuscript is not based on work that has been previously presented/ published.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Explanation: The average values (minimal, maximal values) of SCORAD, EASI, POEM, DLQI are recorded. SCORAD – Scoring of atopic dermatitis, EASI -Eczema Area and Severity Index, POEM - Patient Oriented Eczema Measure, DLQI - Dermatology Life Quality Index.

Explanation: The count of ILCs and their subsets in AD patients with and without dupilumab therapy compared to control group. The median value is recorded. DUP – patients without dupilumab treatment, DUP + patients with dupilumab treatment. ILC innate lymphoid cells, ILC −1, ILC-2, ILC-3, ILC-3 NCR+, ILC-3 NCR- subsets of ILCs. We show the significant difference in statistical analysis, p – value < 0.05. An empty field for the p- value means that no significant difference was found.

Additional information

Funding

Charles University, Medical Faculty Hradec Králové, Cooperation, INDI 207034 (the financial support was intended for research purposes to examine the immunological profile). Supported by MH CZ - DRO (UHHK, 00179906). The Service Fee was funded by the authors.